MedTrace Logo

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

NCT04087473 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-13

No results posted yet for this study

Summary

The investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection. This study will provide a better understanding of ALK resistance in the treatment of Asian lung cancers and allow for improved clinical outcomes by 'matching' the secondary mutations to an ALK inhibitor which would allow for the greatest coverage ultimately leading to lasting duration of response.

Conditions

Sponsors & Collaborators

  • Guardant Health AMEA, Inc.

    collaborator UNKNOWN

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Daniel SW Tan, BSc, MBBS, PhD · National Cancer Centre of Singapore

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-23
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Hong Kong
  • Malaysia
  • Singapore
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087473 on ClinicalTrials.gov